Iveric Bio Inc Stock Price, News & Analysis

IVERIC bio, Inc. (NASDAQ: ISEE) granted equity-based awards on December 1, 2021, to six newly-hired employees as part of its 2019 Inducement Stock Incentive Plan. The grants include non-statutory stock options for 160,000 shares at an exercise price of $14.12 and 21,000 restricted stock units across three tranches. The stock options have a ten-year term and vest over four years, while the restricted stock units have varying vesting schedules. These grants aim to incentivize employee retention and align compensation with performance.

Iveric Bio, trading under the symbol ISEE, announced that CEO Glenn P. Sblendorio and President Pravin U. Dugel, M.D., will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 10:40 a.m. ET. Investors can access the audio webcast on the Iveric Bio website's Investor/Events & Presentations section, with an archived replay available for 30 days following the event. Iveric Bio focuses on developing treatments for retinal diseases, including age-related macular degeneration.

Iveric Bio (ISEE) announced the completion of enrollment in its GATHER2 Phase 3 clinical trial for Zimura® aimed at treating geographic atrophy due to age-related macular degeneration (AMD). Patient retention exceeds expectations with an injection fidelity rate over 90%. Preparations for a New Drug Application (NDA) are underway, anticipating topline data in late 2022. The FDA has approved a Special Protocol Assessment for GATHER2, further enhancing the trial's validity. Financially, the company reported a net loss of $24.6 million for Q3 2021, with cash reserves projected to fund operations until mid-2024.

Iveric Bio (Nasdaq: ISEE) will present at the Credit Suisse 30th Annual Virtual Healthcare Conference on November 9, 2021, at 11:20 a.m. ET. CEO Glenn P. Sblendorio and President Pravin U. Dugel, M.D. will participate in a fireside chat, which can be accessed via www.ivericbio.com. An archived replay will be available post-conference for 30 days. Iveric Bio focuses on innovative treatments for retinal diseases, aiming to significantly improve patient outcomes.

Iveric Bio (NASDAQ: ISEE) announced the grant of equity-based awards on November 1, 2021, to two newly-hired, non-executive employees under its 2019 Inducement Stock Incentive Plan. These awards include non-statutory stock options for 115,000 shares with an exercise price of $17.81, and 16,000 restricted stock units. The options vest over four years, while the restricted stock units have varying vesting schedules. This initiative aims to attract talent to advance the company’s focus on developing treatments for retinal diseases.

Iveric Bio (NASDAQ: ISEE) will release its third quarter 2021 financial results on November 9, 2021, at 8:00 a.m. ET. A conference call will follow to discuss these results and provide a business update. Interested participants can join by calling 1-888-317-6003 (USA) or 1-412-317-6061 (International), using passcode 0259351. The call will be available via audio webcast on the Iveric Bio website. The company is focused on developing treatments for retinal diseases, including age-related macular degeneration.

IVERIC bio, Inc. (ISEE) has priced an upsized public offering of 9,000,000 shares of common stock at $16.75 per share, expected to generate gross proceeds of approximately $150.8 million. The offering includes an underwriter option for 1,350,000 additional shares. Closing is anticipated on or about October 26, 2021, subject to customary conditions. Morgan Stanley, Cowen, Stifel, and Credit Suisse are the book-running managers. The offering is conducted under an automatically effective registration statement, and details are to be filed with the SEC.

IVERIC bio, Inc. (ISEE) is initiating an underwritten public offering of $125 million in common stock, with a 30-day option for underwriters to purchase an additional 15%. The offering's completion is contingent upon market conditions, and specifics on size and terms remain uncertain. Morgan Stanley, Cowen, Stifel, and Credit Suisse are managing the offering. A shelf registration was filed with the SEC on October 21, 2021, and interested parties can find related documentation and prospectuses on the SEC's website.

Iveric Bio (NASDAQ: ISEE) announced on October 1, 2021, the granting of equity-based awards to eight newly-hired employees as part of its 2019 Inducement Stock Incentive Plan. These inducement grants include non-statutory stock options for 375,000 shares and two tranches of 49,000 restricted stock units. The stock options have an exercise price of $16.65 and will vest over four years. Iveric Bio focuses on developing innovative treatments for retinal diseases, aiming to address significant unmet medical needs in the field.